Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

GILD - Gilead Sciences, Inc. Latest News | Finranks

Home

GILD

G

Gilead Sciences, Inc. (GILD)

NMS – Real Time Price. Currency in USD

134.25

-2.63 (-1.92%)

At close: Mar 27, 2026, 4:00 PM EDT

133.88

-0.37 (-0.28%)

After-hours: Mar 27, 2026, 7:51 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Why Gilead Sciences (GILD) Dipped More Than Broader Market Today

Why Gilead Sciences (GILD) Dipped More Than Broader Market Today

Gilead Sciences (GILD) closed the most recent trading day at $134.25, moving 1.92% from the previous trading session.

Here's Why Gilead Sciences (GILD) is a Strong Value Stock

Here's Why Gilead Sciences (GILD) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?

Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Can Gilead's Recent Acquisitions Strengthen Its Long-Term Growth Outlook?

Can Gilead's Recent Acquisitions Strengthen Its Long-Term Growth Outlook?

Gilead doubles down on acquisitions, adding immunology and CAR-T assets to diversify beyond HIV and strengthen its oncology pipeline.

Gilead Strengthens Inflammation Portfolio With Ouro Medicines Deal

Gilead Strengthens Inflammation Portfolio With Ouro Medicines Deal

GILD expands into autoimmune therapies with an acquisition deal with Ouro Medicines, adding OM336 and advancing its push into next-gen immunology platforms.

Gilead Sciences to acquire Ouro Medicines, expanding autoimmune therapy portfolio

Gilead Sciences to acquire Ouro Medicines, expanding autoimmune therapy portfolio

Gilead Sciences Inc (NASDAQ:GILD, XETRA:GIS) announced it has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotech company developing T cell engager therapies for autoimmune diseases. The acquisition adds OM336 (gamgertamig), a clinical-stage BCMAxCD3 bispecific T cell engager, to Gilead's inflammation portfolio.

Gilead to Buy Ouro Medicines for $2.2 Billion. ‘Immune Reset' Is Key to Future Gains.

Gilead to Buy Ouro Medicines for $2.2 Billion. ‘Immune Reset' Is Key to Future Gains.

Gilead plans to develop Ouro's lead drug candidate, gamgertamig, alongside a Belgian pharma company.

Videos

5 Stocks to Buy in a High-Risk Bull Market

Johanna Mercier on Gilead's HIV prevention innovation

Press releases

Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases

Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today it has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases. The acquisition adds OM336 (gamgertamig), a clinical‑stage BCMAxCD3 T cell engager, to Gilead's growing inflammation portfolio. OM336 is designed to enable rapid and deep B cell depletion following a limited subcutaneously admi.

12.01.2026

Positive

Gilead Sciences CEO Daniel O'Day: We have the most robust pipeline in company history

Final Trade: F, HAL, MA, GILD

Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX

Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Arcellx, Inc. (NasdaqGS: ACLX) to Gilead Sciences, Inc. (NasdaqGS: GILD). Under the terms of the proposed transaction, shareholders of Arcellx will receive $115.00 per share in cash plus one contingent value right of $5.00 per share upon the achievement of certain milestones. KSF is seeking to deter.

Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia

Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia

FOSTER CITY, Calif.--(BUSINESS WIRE)--GILEAD FOUNDATION AWARDS $12 MILLION TO EMPOWER COMMUNITY HEALTH WORKERS AND EXPAND HIV PREVENTION INITIATIVES ACROSS THE US.

Gilead's Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy

Gilead's Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #CROI2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new Phase 3 ARTISTRY-1 and ARTISTRY-2 trial data at CROI 2026 showing a treatment switch to an investigational, single-tablet combination regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) was effective in people living with HIV with virological suppression, including those switching from complex multi-tablet regimens or a global guideline-recommended single-tablet regimen. The n.